Abemaciclib in Newly Diagnosed Meningioma Patients

Phase 2

Recruiting

• Conditions: Meningioma
• Interventions: Drug: Placebo; Drug: Abemaciclib

• Registration Number: NCT05940493
• Lead Sponsor: Nader Sanai

Brief Summary

This study is being done to learn about how an investigational drug called abemaciclib works in treating patients with a newly-diagnosed grade 3 meningioma. Abemaciclib is a drug that is approved by the FDA, but not for brain tumors.

Participants who consent to the trial will have surgical tissue collected from the planned surgical resection and tested. If the tissue shows positive results for RB cells and participants are qualified, they will be enrolled and receive study treatment two to five weeks after completing standard-of-care radiation therapy.

This is a randomized clinical trial which means that participants will be randomly assigned to a treatment based on chance, like a flip of a coin. Neither the participant nor the researcher chooses the assigned group. Randomization will help the researchers study how the drug works by comparing the difference between the study drug and the placebo and how they work in treating brain tumors. This is a double-blinded study, which means that neither the participant nor the study team will know which treatment the participant is receiving.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2023-07-04
• Study First Submitted QC: 2023-07-04
• Study First Posted: 2023-07-11
• Status Verified: 2025-02
• Study Start: 2025-03-24
• Last Update Submitted: 2025-09-29
• Last Update Posted: 2025-10-01
• Primary Completion: 2028-09
• Study Completion: 2030-09-01

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 72

Inclusion Criteria

• Participants with newly diagnosed intracranial WHO Grade 3 meningioma; or,

• Participants with previous lower grade meningioma and histopathologically confirmed newly transformation to Grade 3.

• Plan to receive or have received upfront standard of care radiation therapy (RT) for the newly diagnosed WHO Grade 3 meningioma.

• No prior treatment for Grade 3 meningioma other than surgical resection or biopsy and upfront RT. If previously diagnosed with a lower grade meningioma, no prior treatment other than surgical resection or biopsy and no prior RT.

• Ability to understand and the willingness to sign a written informed consent document (personally or by the legally authorized representative, if applicable).

• Participant has voluntarily agreed to participate by giving written informed consent (personally or via legally authorized representative[s], and assent, if applicable). Written informed consent for the protocol must be obtained prior to any screening procedures. If consent cannot be expressed in writing, it must be formally document and witnessed, ideally via an independent trusted witness. Participant must be willing and able to comply with scheduled visits, treatment plans, laboratory tests and other procedures.

• Age ≥18 years at time of consent.

• Have a performance status (PS) of ≤2 on the Eastern Cooperative Oncology Group (ECOG) scale.

• Ability to swallow oral medications.

• Participant has adequate bone marrow and organ function as defined by the following laboratory values (as assessed by the local laboratory for eligibility):

  • Adequate Bone Marrow Function: absolute neutrophil count ≥1,500/mcL, platelets ≥100,000/mcL, and hemoglobin ≥8.0 g/dL (individual may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator; initial treatment must no begin earlier than the day after any erythrocyte transfusion).
  • Adequate Hepatic Function: total bilirubin ≤1.5x ULN (individuals with Gilbert's syndrome with a total bilirubin ≤2.0x ULN and direct bilirubin within normal limits are permitted), AST/SGOT ≤3x ULN, and ALT/SGPT ≤3x ULN.

• Confirmed negative serum pregnancy test (β-hCG) before starting study treatment or participant who is no longer of childbearing potential due to surgical, chemical, or natural menopause.

• For females of reproductive potential: use of highly effective contraception during study participation and for an additional 3 weeks after the end of treatment administration.

• For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner and for an additional 3 weeks after the end of treatment administration.

Exclusion Criteria

• Prior history of cancer with ongoing treatment of disease.
• Pregnancy or breastfeeding.
• Known allergic reactions to components of the abemaciclib.
• Active infection or fever >38.5°C requiring systemic antibiotic, antifungal or antiviral therapy within 4 weeks of Day 1.
• Known to have active (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis, decompensated liver disease, and active and chronic hepatitis.
• Known active systemic bacterial infection (requiring IV antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known HIV positivity or with known HBV or HCV). Screening is not required for enrollment.
• Participant has serious and/or uncontrolled preexisting medical condition(s) that, in the judgment of the investigator, would preclude participation in this study.
• Prior therapy with any CDK4/6 inhibitor. Prior therapy is defined as therapeutic dosing.
• Treatment with another investigational drug within 5 half-lives of the investigational product.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Placebo	Placebo	Administered twice daily on days 1-28 of each 28-day cycle.
Active Treatment (Abemaciclib)	Abemaciclib	Administered twice daily on days 1-28 of each 28-day cycle.

Primary Outcome Measures

Name	Time	Method
Progression-free survival	24 months	Progression free survival (PFS24) rate measured from the time of surgery to date of recurrence

Secondary Outcome Measures

Name	Time	Method
Drug-related toxicity	Up to 30 days after last study dose	Incidence of drug-related toxicity
Progression-free survival in participants	12 months	12 month progression-free survival (PFS12) rate measured from the time of surgery to date of recurrence.
Overall Survival	24 months	Overall survival at 24 months
Median Overall Survival	5 years	Median overall survival
Adverse Events	Up to 30 days after last study dose	Number of adverse events through study completion
Deaths	24 months	Number and incidence of deaths
Incidence of clinical laboratory abnormalities per CTCAE	Up to 30 days after last study dose	Clinical laboratory abnormalities per CTCAE

Trial Locations

Locations (1)

St. Joseph's Hospital and Medical Center; 🇺🇸 Phoenix, Arizona, United States